The PD-1 inhibitor camrelizuab is joining the ranks of immune checkpoint inhibitors proving their worth when added to neoadjuvant chemo for resectable stage III non-small cell lung cancer in a prospective randomized phase 2 trial, this one with 88 Chinese enrollees. The primary endpoint of pathologic complete response was increased from 9 → 33%, much like that seen with the PD-L1 inhibitor nivolumab on NADIM II (7 → 37%). | Lei, JAMA Oncol 2023
